NASDAQ:SCNI Scinai Immunotherapeutics Q4 2025 Earnings Results & Report $0.40 0.00 (0.00%) Closing price 11/13/2026 03:58 PM EasternExtended Trading$0.42 +0.02 (+5.25%) As of 11/13/2026 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Scinai Immunotherapeutics reported Q4 2025 earnings on April 1, 2026. The company reported EPS of $38.00, while revenue was $269 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateApril 1, 2026TimeAfter Market ClosesConference Call7:00 AM ET Scinai Immunotherapeutics EPS ResultsActual EPS$38.00Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AScinai Immunotherapeutics Revenue ResultsActual Revenue$269 thousandExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsScinai Immunotherapeutics' Q3 2026 earnings is estimated for Wednesday, December 2, 2026, based on past reporting schedulesConference Call ResourcesPress Release (6-K)Annual Report (20-F)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(6-K)Annual report(20-F) Scinai Immunotherapeutics Q4 2025 Earnings FAQ Did Scinai Immunotherapeutics beat earnings estimates for Q4 2025? Scinai Immunotherapeutics (NASDAQ:SCNI) reported earnings of $38.00 per share for Q4 2025. The report was announced on Wednesday, April 1, 2026. What was Scinai Immunotherapeutics' revenue for Q4 2025? Scinai Immunotherapeutics reported revenue of $269 thousand for Q4 2025. When is Scinai Immunotherapeutics' next earnings date? Scinai Immunotherapeutics' next earnings date is estimated for Wednesday, December 2, 2026. MarketBeat tracks confirmed and estimated earnings dates for Scinai Immunotherapeutics on the company's earnings history page. Scinai Immunotherapeutics Earnings HeadlinesScinai's Nine-Month Revenue Jumps 167% As CDMO Orders Exceed $8 MlnNovember 5, 2026 | rttnews.comScinai Reports Significant Revenue Growth in First Nine Months of 2026 as CDMO Business ExpandsNovember 5, 2026 | prnewswire.comThe warning signs most investors see too lateDr. Martin D. Weiss has publicly predicted six major American crashes since founding Weiss Ratings in 1971. Now, after 55 years of market analysis, he says conditions are forming for a financial crisis that could rival or exceed 2008. | Weiss Ratings (Ad)Scinai Immunotherapeutics Ltd.: Scinai CEO Updates Shareholders on CDMO Growth and Extended Runway Following Completed FinancingOctober 20, 2026 | finanznachrichten.deScinai CEO Updates Shareholders on CDMO Growth and Extended Runway Following Completed FinancingOctober 20, 2026 | prnewswire.comScinai Immunotherapeutics Announces Closing of $4.0 Million Financing Through a Private Placement and Warrant InducementOctober 16, 2026 | prnewswire.comSee More Scinai Immunotherapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Scinai Immunotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Scinai Immunotherapeutics and other key companies, straight to your email. Email Address About Scinai ImmunotherapeuticsScinai Immunotherapeutics (NASDAQ:SCNI) Ltd. (NASDAQ:SCNI) is an Israel-based clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for autoimmune and inflammatory diseases. The company’s research is centered on treatments intended to modulate disease-related immune responses while potentially limiting systemic exposure and associated side effects. Scinai’s technology platform is based on NanoAb antibody fragments, which are designed to bind specific biological targets and may be suitable for local administration. The company has focused its development efforts on therapies for inflammatory skin conditions, including plaque psoriasis, with programs directed at interleukin-17A, a cytokine associated with inflammatory and autoimmune disorders. In addition to advancing its own product candidates, Scinai has indicated that its NanoAb platform may support partnerships and licensing opportunities for the development of other targeted immunotherapies. The company is headquartered in Israel and conducts its research and development activities through its proprietary platform and external collaborations.View Scinai Immunotherapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/13Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCerebras Q3 Results: How Much More Proof Does Wall Street Need?Applied Materials Beats and Raises, But Investors Stay Unconvinced3 Power and Grid Stocks That Could Keep Growing Even if AI Spending SlowsYETI Beat on Earnings, But Its Sales Tell a Different Story Upcoming Earnings Walt Disney (11/17/2026)Home Depot (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.